AparnaBio
 
작성일 : 13-12-18
[AparnaBio] InVivoPlex® - Tumor / cRGD
RNAi Nanoparticle System for Murine Cancer Models
 
InVivoPlex® - Tumor / cRGD
 
 
InVivoPlex® - Tumor
 
The InVivoPlex®–Tumor Kit is provided for studies in xenograft tumor models with leaky vasculature where the EPR delivery mechanism is active.  Vascularization of tumors results in localization of the nucleic acid nanoparticle in tumor tissue by
an EPR mechanism.  The design of the InVivoPlex®–Tumor nanoparticle enables delivery of nucleic acid activity into tumor
tissue while minimizing activity in organs.  Effective tumor localization and avoidance of lung tissue can be evaluated
easily with the small Kit using a reporter gene plasmid for expression, luciferase is recommended.  The resulting knowledge
about specific parameters of the tumor model giving tumor selective gene delivery allows design of tumor growth inhibition
and gene function studies in the selected tumor model using the large Kit.  The figure below is an example of EPR
mediated delivery of luciferase plasmid nanoparticle in U-87 tumor model that shows tumor localized luciferase
expression several fold higher than the expression in other organs.
 
 
클릭하시면 닫힙니다.이미지 저장을 원하시면 마우스 오른쪽클릭후 '다른이름으로 저장'을 하세요
 
Tumor selective activity of InVivoPlex®–Tumor Panel A: 200 uL dose tail vein InVivoPlex®-Tumor with 60 ug pCI-
Luc to nude mice bearing U87 subcutaneous tumors, expression after 24 hr, normalized with total protein. Panel B: Ratio of
tumor to lung expression, comparing non-targeted PEI to InVivoPlex® –Tumor (n=8).
 
 
InVivoPlex® - cRGD
Neovasculature Targeted RNAi Nanoparticles
 
The InVivoPlex®–cRGD reagent is designed for translation studies in murine models with neovasculature targeting.  
Neovascularization of tumors, angiogenesis, is a well known phenomena and one clinically validated for therapeutic
intervention.  The integrin targeting design of the InVivoPlex®–cRGD nanoparticle reagent enables delivery of nucleic acid
activity to tumor neovasculature as well as nearby tumor tissue, while minimizing activity in organs.  Effective neovasculature tumor localization and avoidance of lung tissue can be evaluated easily using reporter gene plasmid expression,
luciferase is recommended.  The resulting knowledge about specific parameters of the tumor model giving tumor selective
gene delivery allows design of tumor growth inhibition and gene function studies in the selected tumor model using the
InVivoPlex®cRGD Kit. The figure below is an example of integrin targeted InVivoPlex®–cRGD mediated delivery of a
clinically validated VEGF pathway siRNA in a subcutaneous U87MG tumor model that shows tumor growth inhibition
comparable to that by a clinical antibody therapeutic for VEGF.
 
 
Features
  • Simple to use kits form RNAi nanoparticles <100 nm, and stable for 1 week
  • Highly selective uptake by murine neovasculature, minimual lung uptake
  • Low toxicity and low levels of cytokine induction, minimizing off-target effects
  • Clinical relevance: multiple dose regimens, dose response, effect simulates targeted therapy
  • Delivers siRNA or miRNA oligonucleotides, plasmids, and combinations
 
 
Tumor Targeted, Therapeutic RNAi Nanoparticle Capabilities
  • Tumor Selectivity: Delivery is directed to neovasculature, away from organs
  • Repeat Dosing: Administer 3-7 times per week for multiple weeks
  • Dose Response: Evaluate dosages from 1 mg/kg/wk to 10 mg/kg/wk
  • Many Models: Many murine cancer models exhibit neovasculature active tumors
  • Multiple Cargos: siRNA, miRNA, plasmids, and combinations can be delivered
 
클릭하시면 닫힙니다.이미지 저장을 원하시면 마우스 오른쪽클릭후 '다른이름으로 저장'을 하세요
Tumor siRNA activity by co-delivery with plasmid. Mice bearing U87 tumors were treated i.v. with InVivoPlex™ –
TUMOR with 40 ug pCI-Luc plasmid (yellow) versus 40 ug pCI-Luc plus 20 ug Qiagen All-Star negative control siRNA (green)
or 20 ug anti-Luc siRNA (red). n=8
 
To learn more about murine safety of InVivoPlex® kits go to Excellent Safety .
 
 
Ordering inforamtions
 
Catalog No.
Product Name
Size
IVP-T-S
InVivoPlex®–Tumor Kit
540 ug (마우스 6~7마리의 양)
IVP-T-M
720 ug (마우스 8~9마리의 양)
IVP-T-L
900 ug (마우스 10~12마리의 양)
IVP-R-S
InVivoPlex®–cRGD Kit
540 ug
IVP-R-M
720 ug
IVP-R-L
900 ug
 
* InVivoPlex® reagent kits are provided for use with different amounts of nucleic acid (not provided) to accommodate various animal group numbers.  InVitroPlexTM Express reagents are used at a ratio of 2 ul/ug nucleic acid.  The separate
InVitroPlexTM Enhancing Buffer is the same amount provided in the 2 ml InVitroPlex kits.  For larger reagent amounts or
animal studies, please contact us.
 
 
▣ 관련 페이지 ; AparnaBio